MaxCyte Inc - cell and gene therapies firm - Announces expansion of subsidiary CARMA Cell Therapies' ongoing Phase I intraperitoneal delivery and dose-escalation trial of MCY-M11. Says expansion will involve the inclusion of additional patients and the initiation of two additional clinical sites. The new parallel Phase I cohort with the additional patients will evaluate intraperitoneal delivery of MCY-M11 at escalating doses in additional patients with relapsed/refractory ovarian cancer and malignant peritoneal mesothelioma.
"We are very pleased with the progress of this first-in-human trial to date, and have great hopes that we are moving closer towards bringing a more effective immunotherapeutic option for patients with solid tumors," said MaxCyte's Chief Medical Officer Claudio Ullmann.
Current stock price: 347.00 pence
Year-to-date change: up almost three-fold.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
MaxCyte (MXCT)